Comment
Amgen disputes points in "Legal Angle" column
- PMID: 2073269
Item in Clipboard
Comment
Amgen disputes points in "Legal Angle" column
Nephrol News Issues.
1990 Oct.
No abstract available
Comment on
-
EPO--one year later. Fighting anemia in the courtroom.Nephrol News Issues. 1990 May;4(5):27. Nephrol News Issues. 1990. PMID: 2348877 No abstract available.
Similar articles
-
Amgen protects its billion dollar protein.Nat Biotechnol. 1997 Jun;15(6):496-7. doi: 10.1038/nbt0697-496. Nat Biotechnol. 1997. PMID: 9181560 No abstract available.
-
EPO (epoetin) approval stirs cost concern in Congress.Mod Healthc. 1989 Jun 9;19(23):4. Mod Healthc. 1989. PMID: 10293460 No abstract available.
-
EPO--one year later. Fighting anemia in the courtroom.Nephrol News Issues. 1990 May;4(5):27. Nephrol News Issues. 1990. PMID: 2348877 No abstract available.
-
Resistance to recombinant human erythropoietin therapy: a real clinical entity?Semin Nephrol. 1989 Mar;9(1 Suppl 2):8-11. Semin Nephrol. 1989. PMID: 2669085 Review.
-
Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?ASAIO J. 1993 Jan-Mar;39(1):11-8. ASAIO J. 1993. PMID: 8439674 Review. No abstract available.